Clonal hematopoiesis of indeterminate potential and risk of death from COVID-19
Peter G. Miller, Geoffrey Fell, Brody H. Foy, Allison K. Scherer, Christopher J. Gibson, Adam S. Sperling, Bala Bharathi Burugula, Tetsushi Nakao, Md Mesbah Uddin, Hailey M. Warren, Lynn Bry, Olga Pozdnyakova, Matthew J. Frigault, Alex G. Bick, Donna Neuberg, John M. Higgins, Michael K. Mansour, Pradeep Natarajan, Annette S. Kim, Jacob O. Kitzman, Benjamin L. Ebert
Abstract
Two Letters to Blood address the risks of COVID-19 in populations with precursors of hematological disease. In the first article, Miller and colleagues report on whether clonal hematopoiesis of intermediate potential (CHIP) is associated with adverse outcomes with COVID-19, finding no association between CHIP and 28-day mortality while providing data indirectly linking IL-6 signaling and patient outcomes. In the second article, Ho and colleagues investigate the outcomes of patients with monoclonal gammopathy of undetermined significance (MGUS) with COVID-19, reporting that one-fourth had a severe infection and that on multivariable analysis, adverse outcomes are more likely if immunoparesis is present.